Doubly dangerous: Extranodal NK/T-Cell Lymphoma

The patient ’s disease was already very advanced when the diagnosis was determined, and a hazardous complication was developing as well. A 63-year-old woman presented with a 2-month history of symmetrical violaceous swelling of the face (Figure 1A). Faint violaceous patches also marked her neck, upper chest, upper back, and both arms (Figure 1B). In addition, she had been suffering from a sore throat for the previous 3 weeks, and on the day before admission, she developed an intermittent fever. One month earlier, physicians at a local hospital arrived at a possible diagnosis of dermatomyositis, based on the patient’s clinical presentation and on skin biopsy results that showed interface dermatitis.
Source: The American Journal of Medicine - Category: Journals (General) Authors: Tags: Images in Dermatology Source Type: research

Related Links:

Long-term data show better overall survival after an allogeneic transplant for relapsed follicular lymphoma than with autologous transplant, but an expert wonders about recommending transplant at all.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ConclusionThis case emphasizes the importance of considering cutaneous secondary syphilis in the differential diagnosis of any inflammatory cutaneous disorder in individuals infected with human immunodeficiency virus.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Conclusions: CD200 has a great impact in diagnosing B- chronic lymphoproliferative disorders, especially when we want to determine the origin of a CD19, CD5 positive population and distinguish between CLL and MCL. CD 23 is a reliable marker in those cases, but, as we showed, CD23 might have a lower specificity than CD200 for CLL. We added CD200 in our panels in order to diagnose chronic lymphoproliferative disorders, not to replace CD 23, but to improve and save time in our diagnostic process. The high expression of CD200 in CLL and HCL could open the option for new- targeted therapy (anti-CD200). PMID: 31803290 [PubMed]
Source: Journal of Medicine and Life - Category: General Medicine Tags: J Med Life Source Type: research
Publication date: Available online 7 December 2019Source: Urology Case ReportsAuthor(s): Margaret M. Mansbridge, Jonathon R. Parker, Sewwandi Francisco, Scott T. McClintockAbstractIncidental diagnosis of haematolymphoid disorders in prostate tissue is rare, with the largest study in the literature reporting a 0.37% incidental lymphoma diagnosis in prostate and associated lymph node tissue. B cell lymphocytosis (MBL) is a relatively recently defined disease entity. The authors present the diagnosis and management of a patient diagnosed with incidental MBL on transurethral resection of prostate (TURP), performed for symptoma...
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
In conclusion, these data indicate that ZFAS1 may serve as an oncogene in APL and may thus be a useful target for future clinical management. PMID: 31807158 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
(Georgetown University Medical Center) People with follicular lymphoma, a slow-growing lymphatic-system cancer, who have been treated and are in remission for at least two years, may no longer have what has been considered an incurable disease based on highly sensitive testing; this means they no longer need therapy or active follow-up.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(SWOG) Most people diagnosed with the most common type of non-Hodgkin's lymphoma can safely skip radiation treatment after a clear PET scan, according to new clinical trial results released today at the 61st American Society of Hematology (ASH) Annual Meeting.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
The combination use of polatuzumab-vedotin, obinutuzumab, and lenalidomide showed high complete response rates in patients with relapsed/refractory follicular lymphoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
A novel bispecific antibody, mosunetuzumab, has shown complete remissions in patients with poor prognosis non-Hodgkin's lymphoma, even those previously treated with CAR T cells.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
We examined our primary care birth cohort of 158,510 pediatric patients, of whom 214 patients met 2017 FPIES diagnostic criteria. We measured the influence of FPIES on developing subsequent atopic disease.ResultsPediatric FPIES incidence was between 0.17% and 0.42% depending on birth year. As in prior reports, most patients had an acute presentation (78%), and milk, soy, oat, rice, potato, and egg were common triggers. The mean age of diagnosis was 6.8 months. Atopic comorbidity was higher in patients with FPIES compared with healthy children (AD, 20.6% vs 11.7%; IgE-FA, 23.8% vs 4.0%; asthma, 26.6% vs 18.4%; AR, 28.0% vs 16.7%; P
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
More News: Dermatitis | Dermatology | Dermatomyositis | General Medicine | Hospitals | Lymphoma | Skin | Skin Biopsy | Sore Throat | T-cell Lymphoma